Untitled Document
[an error occurred while processing this directive]
www.expresspharmaonline.com FORTNIGHTLY INSIGHT FOR PHARMA PROFESSIONALS
16-30 April 2006  
Untitled Document
Sections

Market
Logistics
Management
Research
Pharma Life

Services
Open Forum
Subscribe/Renew
Archives
Contact Us
Events
Pharma Excellence Awards
Network Sites
Express Computer
Network Magazine India
Express Hospitality
Express TravelWorld
feBusiness Traveller
Exp. Healthcare Mgmt.
Express Textile
Group Sites
ExpressIndia
Indian Express
Financial Express

Partner Assns.
Home - Market - Article

Company Watch

Zydus Cadila files IND application for NME - ZYH2

Our News bureau - Mumbai

Zydus Cadila has filed another IND (Investigational New Drug) application for the New Molecular Entity (NME)— ZYH2 with the Drug Controller General of India (DCGI). The novel agent for treating diabetes has been designed and developed by Zydus Research Centre, the research wing of Zydus Cadila. With this filing, Zydus Cadila has filed three INDs - ZYH1, ZYH and ZYH2. The NME - ZYH1 has now entered Phase II clinical trials.

`ZY H2', has displayed a unique profile in pre-clinical studies. The NME has the potential to improve insulin resistance and lower blood glucose in diabetic conditions without causing hypoglycemia. It also works favourably to lower the elevated lipid levels.

It is estimated that there are 30 to 33 million diabetics in India now, and every fourth diabetic in the world, today, is an Indian. Indians are genetically more susceptible to diabetes, and the World Health Organization predicts the number of diabetics in India would go up to 40 million by 2010 and 74 million by 2025, making it the diabetes capital of the world.

In recent times, glitazones (rosiglitazone and pioglitazone) have been launched to treat increasing prevalence of insulin resistance in Type - II diabetes. The pre-clinical studies on ZYH2 indicate that this NME may be more effective for diabetics by improving insulin resistance and lowering blood glucose levels without causing hypoglycemia and in also controlling the elevated tryglycerides level which are commonly found in such patients and may require special intervention.

 


[an error occurred while processing this directive]
404 - Error: 404

An error has occurred.
The requested page cannot be found.

If difficulties persist, please contact the System Administrator of this site and report the error below.

#404 Category not found


[an error occurred while processing this directive]
[an error occurred while processing this directive]
[an error occurred while processing this directive]
[an error occurred while processing this directive]
[an error occurred while processing this directive]
Untitled Document
Copyright 2001: Indian Express Newspapers (Mumbai) Limited (Mumbai, India). All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of the Indian Express Newspapers (Mumbai) Limited. Site managed by BPD.